Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed ...

Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price cut by The Goldman Sachs Group from $18.00 to $14.00 in a research report report published on Thursday morning,Benzinga reports.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal ...

SALT LAKE CITY - A recent study published in the Journal of Clinical Psychopharmacology indicates that the use of the GeneSight Psychotropic Test by Myriad Genetics, Inc. (NASDAQ: MYGN), a ...